Vanda Pharmaceuticals Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Vanda Pharmaceuticals Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $216.11M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $198.77M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $192.64M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $254.38M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $268.68M | Feb 8, 2024 |
| FY2020 | Dec 31, 2020 | $67.65M | Feb 11, 2021 |
| FY2020 | Sep 30, 2020 | $60.31M | Feb 11, 2021 |
| FY2020 | Jun 30, 2020 | $62.21M | Feb 11, 2021 |
| FY2020 | Mar 31, 2020 | $58.00M | Feb 11, 2021 |
| FY2020 | Dec 31, 2019 | $60.93M | Feb 11, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $216.11M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $198.77M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $192.64M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $254.38M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $268.68M | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | $248.17M | Feb 9, 2023 |
| FY2021 | Dec 31, 2019 | $227.19M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $193.12M | Feb 11, 2021 |
| FY2019 | Dec 31, 2017 | $165.08M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $146.02M | Feb 19, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2012 | Dec 31, 2012 | $7.92M | Feb 26, 2013 |
| FY2012 | Sep 30, 2012 | $8.29M | Feb 26, 2013 |
| FY2012 | Jun 30, 2012 | $8.38M | Feb 26, 2013 |
| FY2012 | Mar 31, 2012 | $8.14M | Feb 26, 2013 |
| FY2012 | Dec 31, 2011 | $8.37M | Feb 26, 2013 |
| FY2012 | Sep 30, 2011 | $7.97M | Feb 26, 2013 |
| FY2012 | Jun 30, 2011 | $7.43M | Feb 26, 2013 |
| FY2012 | Mar 31, 2011 | $7.50M | Feb 26, 2013 |
| FY2011 | Dec 31, 2010 | $35.71M | Mar 9, 2012 |
| FY2011 | Dec 31, 2009 | $4.55M | Mar 9, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $60.87M | Feb 11, 2021 |
| FY2020 | Sep 30, 2020 | $54.04M | Feb 11, 2021 |
| FY2020 | Jun 30, 2020 | $55.99M | Feb 11, 2021 |
| FY2020 | Mar 31, 2020 | $52.42M | Feb 11, 2021 |
| FY2020 | Dec 31, 2019 | $54.34M | Feb 11, 2021 |
| FY2020 | Sep 30, 2019 | $52.33M | Feb 11, 2021 |
| FY2020 | Jun 30, 2019 | $52.31M | Feb 11, 2021 |
| FY2020 | Mar 31, 2019 | $42.22M | Feb 11, 2021 |
| FY2019 | Dec 31, 2018 | $46.99M | Feb 26, 2020 |
| FY2019 | Sep 30, 2018 | $43.67M | Feb 26, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($220.47M) | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | ($18.90M) | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $2.51M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $6.28M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $33.15M | Feb 8, 2024 |
| FY2020 | Dec 31, 2020 | $8.19M | Feb 11, 2021 |
| FY2020 | Sep 30, 2020 | $5.95M | Feb 11, 2021 |
| FY2020 | Jun 30, 2020 | $8.71M | Feb 11, 2021 |
| FY2020 | Mar 31, 2020 | $486.0K | Feb 11, 2021 |
| FY2020 | Dec 31, 2019 | $4.22M | Feb 11, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($151.17M) | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | ($40.66M) | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | ($13.95M) | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $6.33M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $42.17M | Feb 8, 2024 |
| FY2020 | Dec 31, 2020 | $10.45M | Feb 11, 2021 |
| FY2020 | Sep 30, 2020 | $7.74M | Feb 11, 2021 |
| FY2020 | Jun 30, 2020 | $9.17M | Feb 11, 2021 |
| FY2020 | Mar 31, 2020 | ($125.0K) | Feb 11, 2021 |
| FY2020 | Dec 31, 2019 | $4.24M | Feb 11, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $109.27M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $74.43M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $76.82M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $85.77M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $75.36M | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | $55.58M | Feb 9, 2023 |
| FY2021 | Dec 31, 2019 | $48.65M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $43.59M | Feb 11, 2021 |
| FY2019 | Dec 31, 2017 | $38.55M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $29.16M | Feb 19, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $237.95M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $146.41M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $112.88M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $136.49M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $124.05M | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | $140.51M | Feb 9, 2023 |
| FY2021 | Dec 31, 2019 | $129.74M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $105.75M | Feb 11, 2021 |
| FY2019 | Dec 31, 2017 | $123.84M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $99.79M | Feb 19, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($109.44M) | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | ($15.76M) | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $12.80M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $31.98M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $64.21M | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | $51.78M | Feb 9, 2023 |
| FY2021 | Dec 31, 2019 | $45.95M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $29.99M | Feb 11, 2021 |
| FY2019 | Dec 31, 2017 | ($1.98M) | Feb 26, 2020 |
| FY2013 | Dec 31, 2013 | ($39.59M) | Feb 25, 2014 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $998.0K | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $490.0K | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $383.0K | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $679.0K | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $552.0K | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | $1.80M | Feb 9, 2023 |
| FY2021 | Dec 31, 2019 | $1.02M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $368.0K | Feb 11, 2021 |
| FY2019 | Dec 31, 2017 | $1.66M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $1.41M | Feb 19, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $488.95M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $656.20M | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $648.44M | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $634.25M | Feb 8, 2024 |
| FY2022 | Dec 31, 2021 | $593.79M | Feb 9, 2023 |
| FY2021 | Dec 31, 2020 | $533.46M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $483.75M | Feb 11, 2021 |
| FY2019 | Dec 31, 2018 | $332.13M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $205.43M | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $210.37M | Feb 15, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $161.76M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $117.66M | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $103.53M | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $107.05M | Feb 8, 2024 |
| FY2022 | Dec 31, 2021 | $88.86M | Feb 9, 2023 |
| FY2021 | Dec 31, 2020 | $80.19M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $72.80M | Feb 11, 2021 |
| FY2019 | Dec 31, 2018 | $56.71M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $74.04M | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $79.04M | Feb 15, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $327.19M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $538.55M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $544.91M | Feb 12, 2026 |
| FY2025 | Dec 31, 2022 | $527.20M | Feb 12, 2026 |
| FY2024 | Dec 31, 2021 | $504.93M | Feb 14, 2025 |
| FY2023 | Dec 31, 2020 | $453.27M | Feb 8, 2024 |
| FY2022 | Dec 31, 2019 | $410.95M | Feb 9, 2023 |
| FY2021 | Dec 31, 2018 | $275.42M | Feb 24, 2022 |
| FY2020 | Dec 31, 2017 | $131.39M | Feb 11, 2021 |
| FY2019 | Dec 31, 2016 | $131.33M | Feb 26, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($394.77M) | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | ($174.29M) | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | ($155.39M) | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | ($157.90M) | Feb 8, 2024 |
| FY2022 | Dec 31, 2021 | ($164.18M) | Feb 9, 2023 |
| FY2021 | Dec 31, 2020 | ($197.33M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | ($220.67M) | Feb 11, 2021 |
| FY2019 | Dec 31, 2018 | ($336.22M) | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | ($361.43M) | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | ($345.86M) | Feb 15, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $84.85M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $102.32M | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $135.82M | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $135.03M | Feb 8, 2024 |
| FY2022 | Dec 31, 2021 | $52.07M | Feb 9, 2023 |
| FY2021 | Dec 31, 2020 | $61.03M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $45.07M | Feb 11, 2021 |
| FY2019 | Dec 31, 2018 | $61.01M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $33.63M | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $40.43M | Feb 15, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 8, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 11, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 11, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 11, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 11, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 11, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 8, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 11, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 11, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 11, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 11, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 11, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 59.10M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | 58.31M | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | 57.53M | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | 56.78M | Feb 8, 2024 |
| FY2022 | Dec 31, 2021 | 55.90M | Feb 9, 2023 |
| FY2021 | Dec 31, 2020 | 54.87M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | 53.55M | Feb 11, 2021 |
| FY2019 | Dec 31, 2018 | 52.48M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | 44.94M | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | 44.00M | Feb 15, 2018 |